Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aestus Therapeutics has entered into a license agreement with Astellas Pharma according to which Aestus will get exclusive, world-wide rights to the Astellas product FK614.
Subscribe to our email newsletter
Aestus is expected to develop the product as ATx08-001, a novel therapeutic for the treatment of neuropathic pain. The first clinical trial will start later this year.
Aestus has identified Atx08-001, using proprietary systems biology engine for the analysis of genome-scale expression data.
Atx08-001 is a PPAR-gamma agonist with an unprecedented safety profile, as a potential therapeutic for the treatment of neuropathic pain.
Aestus said that ATx08-001 is more effective than standard treatments in reversing pain behavior in pre-clinical neuropathic pain models.
Furthermore, Aestus is preparing for clinical trials to test the efficacy of ATx08-001 in the treatment of post-herpetic neuralgia (PHN).
Tage Honore, co-founder and CEO of Aestus, said: “We are pleased to enter into this agreement with Astellas to license FK614. The extensive database of human safety studies on FK614 will enable a faster, more efficient process to bring a potential new therapy through the clinical investigations and to market to treat chronic pain. This therapy holds a vast potential to provide a new treatment option to the 39 million people who suffer from chronic pain globally.”